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VACCINATION WITH RECOMBINANT LEISHMANIA DONOVANI
GAMMA-GLUTAMYLCYSTEINE SYNTHETASE FUSION PROTEIN PROTECTS
AGAINST L. DONOVANI INFECTION
F. L. Henriquez, S. A. Campbell*, C. W. Roberts, A. B. Mullen, R. Burchmore`, and K. C. Carter§
School of Science, University of the West of Scotland, Paisley, U.K. e-mail: k.carter@strath.ac.uk
ABSTRACT: Visceral leishmaniasis presents a serious health threat in many parts of the world. There is, therefore, an urgent need for
an approved vaccine for clinical use to protect against infection. In this study, the ability of recombinant Leishmania donovani gamma-
glutamyl cysteine synthetase protein (LdcGCS) alone or incorporated into a non-ionic surfactant vesicle (NIV) delivery system to
protect against L. donovani infection was evaluated in a BALB/c mouse model. Immunization with LdcGCS alone or LdcGCS-NIV
induced specific IgG1 and IgG2a antibodies compared to controls, with LdcGCS-NIV inducing significantly higher titers of both
antibody classes (P , 0.05). Both formulations induced similar increases in splenocyte IFN-c production following ex vivo antigen
stimulation with LdcGCS compared with cells from control mice (P, 0.05). Similar levels of protection against infection were induced
by LdcGCS alone and LdcGCS-NIV, based on their ability to suppress liver parasite burdens compared to control values (P , 0.01),
indicating that using a carrier system did not enhance the protective responses induced by the recombinant protein. The results of this
study indicate that LdcGCS may be a useful component in a vaccine against L. donovani.
Leishmania spp. the causative agent of leishmaniasis, are a
serious health threat in 88 countries. Leishmania donvani causes
the visceral leishmaniasis (VL) and is fatal if untreated. Resistance
to antimonial drugs in certain areas, e.g., Bihar State, India, has
severely reduced the options for clinical treatment. There are
500,000 new cases/yr and 50,000 reported deaths/yr, a figure that
is likely to be an underestimate because VL is often not diagnosed
or reported. Asymptomatic cases occur, with ratios varying from
1:2.6 up to 50:1 clinical cases, depending on the geographical
location, indicating that it should be possible to immunize against
infection (Chappuis et al., 2007). The prevalence of VL co-
infection with human immunodeficiency virus (HIV) is increasing,
and HIV infection can increase the risk of patients developing VL
by 100–2,330 times, reduce their ability to respond to drug
treatment, and increase the probability of disease relapse (Alvar et
al., 2008). This highlights the potential importance and utility of a
prophylactic vaccine to prevent infection. Different types of
candidate vaccines have been tested in experimental systems, for
example, sand fly antigens, defined parasite antigens, or bacteria-
expressing parasite proteins (reviewed by de Oliveira et al., 2009).
A number of candidates have been tested clinically, for example, a
live vaccine for human use in Uzbekistan and a killed vaccine for
human use in Brazil (Palatnik-de-Sousa, 2008). However, to date
no vaccine has been approved for prophylactic use against
leishmaniasis in clinics (Bhowmick and Ali, 2009).
In a previous study, we have shown that immunization with a
plasmid containing the gene sequence for L. donovani gamma-
glutamyl cysteine synthetase (cGCS) protected BALB/c mice
against infection with L. donovani (Carter et al., 2007), but the
level of protection obtained was lower than likely to be clinically
useful. It was possible that better protection would be achieved by
vaccinating with the recombinant protein instead of the DNA
sequence. Therefore, in the present study the ability of L. donovani
cGCS (LdcGCS) to protect against infection was assessed.
Adjuvants have been used to improve the efficacy of protein
vaccines (O’Hagan and De Gregorio, 2009); therefore, in the
present study, the ability of the non-ionic surfactant vesicles
(NIV), which have adjuvant capabilities (Ferro et al., 2004), to
increase the efficacy of LdcGCS vaccination was also evaluated.
The effect of immunization on the production of both Th1- and
Th2-associated immune responses was examined in pre- and post-
infection to determine what type of immune response was
associated with vaccination and whether it correlated with
protection. Immunity to L. donovani is associated with an IL-
12–driven Th1 response and the production of IFN-c, but Th2
responses are also important because the ability to produce the
Th2 cytokine IL-4 is associated with resistance to infection
(Alexander and McFarlane, 2008). It is, therefore, imperative to
identify the immune parameters that correlate with vaccine-
induced protection, as this would help in screening potential
vaccine candidates (Bhowmick and Ali, 2009).
MATERIALS AND METHODS
Reagents
Pharmingen capture and detection anti-IFNc antibodies, IFNc
standard, and alkaline phosphatase conjugate were obtained from Insight
Biotechnology (Wembley, U.K.). All other reagents were of analytical
grade. LPS from Escherichia coli (0111:B4, Sigma-Aldrich, Poole, U.K.)
was used.
Animals and parasites
Age-matched BALB/c female mice (20–25 g) in-house bred at University
of Strathclyde were used in this study. Commercially obtained golden
Syrian hamsters (Mesocricetus auratus; Harlan Olac, Bicester, U.K.) were
used for maintenance of L. donovani strain 200016.
LdcGCS recombinant protein production
The methods detailed in Carter (2007) were used to produce a his-
tagged cGCS recombinant protein. The full-length L. donovani cGCS
protein (GenBank AY371486) was cloned into pET45a (Novagen,
Nottingham, U.K.) using primers designed for PCR: cGCSfor (59-GG
GGT ACC GGG CTC TTG ACG ACT GGC GGC-39) containing a kpnI
site (underlined) and cGCSrev (GGG GGA TCC TCA CTT GGT GCT
CTC TAC CTG containing a BamHI site (underlined). Recombinant
protein was prepared from freshly transfected bacteria using LB broth
containing ampicillin (100 mg/ml), chloramphenicol (10 mg/ml), and
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tetracycline (34 mg/ml) in Rosetta blue E. coli. Protein was induced using
1 mM IPTG, and cells were grown overnight at 30 C. The insoluble
material obtained after passing the bacteria through the French press was
exposed to extraction buffer (0.15 M Tris. 0.2 M KCl, pH 7.4 containing
6 M urea, 20 ml/L culture) for 1 hr. Centrifugation was carried out at
12,000 g at 4 C and the supernatant diluted 1:1 with extraction buffer, and
50 mM imidazole was added before applying to a His-binding agarose
column (GraviTrapH; New England Biolabs, Hitchin, U.K.) as directed.
The bound protein was eluted by adding 10 ml extraction buffer
containing 0.5 M imidazole, and the absorbance of 3 ml fractions was
measured at 280 nm using a GeneQuant Pro spectrophotometer to
quantify the protein concentration. The purified protein aliquots were
pooled and dialyzed against three 1 L batches of PBS, pH 7.4 at 4 C over a
24 hr period. The protein concentration in sample was determined as
directed using the Biorad reagent and BSA as the protein standard.
In some studies expression was carried out in the presence of protease
inhibitors (cOmpleteTM; Roche Diagnostics, Burgess Hill, West Sussex,
U.K.) to prevent protein degradation. Endotoxin was removed from the
purified protein using a ProteoSpin Endotoxin Removal Maxi kit
(Geneflow, Fradley, U.K.), and the amount of endotoxin present in the
sample before and after endotoxin removal was determined by Wickham
Laboratories (Fareham, U.K.). The presence of recombinant LdcGCS
protein was confirmed by carrying out a Western blot using an anti-his
monoclonal antibody (NEB, diluted 1:3,000 with PBS, pH 7.4) for
primary detection and an HRP-rat-anti-mouse IgG monoclonal antibody
(NEB, diluted 1:3,000 with PBS, pH 7.4) for secondary detection. In
addition, samples of major protein bands separated by gel electrophoresis
were analyzed by mass spectrometry. Coomassie-stained protein bands
were excised from SDS-PAGE gels and washed in 100 mM ammonium
bicarbonate with shaking for 1 hr at room temp, followed by a second
wash in 50% acetonitrile/100 mM ammonium bicarbonate. Proteins were
reduced with 3 mM DTT in 100 mM ammonium bicarbonate for 30 min
at 60 C, followed by alkylation with 10 mM iodoacetamide for 30 min in
the dark at room temperature. The gel pieces were washed with 50%
acetonitrile/100 mM ammonium bicarbonate, shaking for 1 hr at room
temp, then dehydrated by incubation with 0.1 ml acetonitrile for 10 min at
room temperature. Gel pieces were dried to completion under vacuum,
then rehydrated with a sufficient volume of trypsin (Promega sequencing
grade, 2 mg/ml in 25 mM ammonium bicarbonate) to cover the gel pieces.
Digest was performed at 37 C overnight. Liquid was transferred to a fresh
tube, and gel pieces washed 10 min with a similar volume of 50%
acetonitrile. This wash was pooled with the first extract, and the tryptic
peptides dried to completion. Tryptic peptides were solubilized in 0.5%
formic acid and fractionated by nanoflow HPLC on a C18 reverse phase
column, eluting with a continuous linear gradient to 40% acetonitrile over
20 min. Eluate was analyzed by online electrospray tandem mass
spectrometry using a Qstar Pulsar (Applied Biosystems, Warrington,
U.K.). Mass spectrometric analysis was performed in IDA mode
(AnalystQS software, Applied Biosystems), selecting the 4 most intense
ions for MSMS analysis. A survey scan of 400–1,500 Da was collected for
3 sec followed by 5 sec MSMS scans of 50–2,000 Da using the standard
rolling collision energy settings. Masses were then added to the exclusion
list for 3 min. Peaks were extracted using the Mascot script (BioAnalyst,
Applied Biosystems) and automatically exported to the Mascot (Matrix
Science, London, U.K.) search engine for searching against both
Leishmania major and E. coli genome datasets.
Production of NIV
Six hundred mmol vesicle constituents, consisting of 3:3:1 molar ratio of
mono-n-hexadecyl ether tetraethylene glycol, cholesterol, and dicetyl
phosphate, were melted by heating at 130 C for 5 min. The molten mixture
was cooled to 70 C, and hydrated with 5 ml of preheated (70 C) water to
form ‘empty’ non-ionic surfactant vesicles (NIV). Vesicular formulations
were homogenized at 8,000 ± 100 g for 15 min at 70 C, using a Silverson
mixer, fitted with a 5/8-inch tubular work head. Two- or 1-ml aliquots of
the NIV were stored at 270 C before freeze-drying overnight then stored
at 220 C until required.
Immunization studies
The day of infection was day 0 so that vaccination occurred pre-
infection on day 228 and day 214. Animals (n 5 5/treatment) were
immunized with either LPS (10 ng/ml equivalent to 5 EU/ml, 1 ng/dose),
LdcGCS (2 or 50 mg, used as prepared or processed to remove endotoxin),
or LdcGCS incorporated into NIV (50 mg) on days 228 and 214. The
dose of LPS used was based on the lowest expected LPS contamination
present in recombinant protein samples. Therefore, animals were exposed
to the lowest dose of LPS, a known pyrogen (Dinarello, 2004). LdcGCS-
NIV was produced by hydrating a 1- or 2-ml aliquot of freeze-dried NIV
with the required amount of LdcGCS protein in PBS, pH 7.4, to the
appropriate volume of 1 or 2 ml with shaking. On day 0 immunized mice
and a control group (n 5 4–10/treatment) were infected by intravenous
injection (tail vein, no anaesthetic) with 1–2 3 107 L. donovani strain
200016 amastigotes harvested from the spleen of an infected hamster.
Parasite burdens in the spleen, liver, and bone marrow were determined on
day 40 post-infection (PI; Carter et al. 2007). All studies were carried out
in accordance with U.K. Home Office regulations.
Assessment of immunological responses
ELISA assays conducted to determine the end point titers of parasite-
specific IgG1 and IgG2a present in the serum, against an L. donovani–
soluble antigen (SAG) or the LdcGCS protein (Carter et al., 2007). At
early time points, the lowest serum dilution tested was 1:100, while at later
time points, when high antibody titers were obtained, the lowest dilution
tested was 1:1,000. Single-cell suspensions, prepared from the spleens of
mice, were used in proliferation assays and incubated with medium alone
(unstimulated controls), Concanavalin A (ConA, 5 mg/ml, stimulated
controls), or LdcGCS protein (25 mg/ml). Cell supernatants were stored at
220 C until nitrite and cytokine were determined as previously described
(Carter et al., 2007).
Statistical analysis
Data from this study were analyzed as described by Carter et al. (2007).
A 1-way ANOVA was used for log10 transformed parasite data and a
Kruskal-Wallis test followed by Dunn’s ad hoc test for cytokine and
nitrite data.
RESULTS
Expression of L. donovani LdcGCS in E. coli Rosetta blue
bacteria resulted in the production of full-length and
truncated LdcGCS protein
Purification of proteins from the insoluble bacterial extract from
transformed bacteria using the GraviTrap column resulted in a
reduction in the number of protein bands present in the sample
(normally 4 main bands) (Fig. 1A, lane 8), with the highest
molecular weight protein (80 kDa, also the most intense band)
corresponding to the expected molecular weight for LdcGCS.
Western blot analysis using antibodies recognising the histidine tag
portion of the expressed protein demonstrated reactivity with the 4
main bands (lane 5, Fig. 1A). Proteins present in the 4 main bands
were excised from a gel after separation by electrophoresis, and the
proteins present determined by tandem MS analysis of tryptic
peptides. Forty-seven tryptic peptides were matched to the 80 kDa
band, giving 66% protein coverage and a MOWSE score of 1808.
However, the smaller bands also gave rise to peptides, which
matched to LdcGCS with very robust MOWSE scores, suggesting
that either degradation of the full-length protein occurred during
processing or that shorter forms of the protein were produced
during expression. Consistent with this interpretation, peptide
coverage was weaker in the carboxy-terminal region of LdcGCS for
the smaller bands. Inclusion of protein inhibitors to prevent protein
degradation during production of LdcGCS had no appreciable
effect on the number of protein bands obtained or HIS-positive
protein bands present in the soluble or insoluble fractions (data not
shown). Importantly, none of the tandem MS data matched
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significantly to E. coli proteins, suggesting that the detected bands
are not contaminants deriving from the recombinant expression
system. Endotoxin contamination was variable between different
batches of recombinant protein, and processing removed .85%
contamination (mean bacterial endotoxin levels: batch 1, pre-
processing 2,576 EU/ml; post-processing ,5 EU/ml; batch 2 pre-
processing 24,140 EU/ml; post-processing 3,430 EU/ml). To
eliminate the possibility that endotoxin contamination could have
been responsible for the anti-leishmanial efficacy of the recombi-
nant protein, LdcGCS was treated to remove any endotoxin.
Immunization with LdcGCS protein induced a mixed
Th1/Th2 response
Mice were immunized with LdcGCS protein alone or LdcGCS
protein incorporated into NIV to determine whether using a
FIGURE 1. Proteins present in the different fractions collected during production of Leishmania donovani LdcGCS S protein after Coomasie staining
(A) or after staining for his-tagged proteins following Western blot studies (B). In Figure 1A, results for 3 batches of LdcGCS protein are shown. M, lane
for molecular weight markers (25–225 KDa), lane 1 uninduced protein sample; lanes 2, 4, and 6 induced protein samples; lanes 3, 5, and 8 protein
samples after purification using GraviTrap column (LdcGCS). Lane 7 induced a soluble protein sample, which contains very little LdcGCS, indicating
that the majority of the protein is in the insoluble fraction. The highest molecular weight band in lane 8 (arrow) correlates to full length LdcGCS. The
difference in intensity between LdcGCS samples in lanes 3, 5, and 8 equates to differences in initial protein concentration. In Figure 1B, M lane for
molecular weight markers (25–100 KDa), lanes 1–5 LdcGCS, increasing amount of protein loaded to show that lower molecular weight bands become
more apparent as the protein concentration increases, e.g., compare lanes 1 and 5, lanes 6 and 7 induced protein samples. Arrow shows full-
length LdcGCS.
FIGURE 2. The effect of vaccination with LdcGCS on pre-infection specific antibody responses of mice. Mice were immunized by subcutaneous
injection with PBS (uninfected control) or 50 mg LdcGCS antigen alone (LdcGCS) or 50 mg LdcGCS incorporated in NIV (LdcGCS-NIV) on days 228
and 214. Specific IgG1 (A) and IgG2a (B) antibody titers to LdcGCS were determined by ELISA on the day before the second immunisation, i.e., day
215, 7 days after the second immunization, i.e., day 27, and on the day mice were infected, i.e., day 0. Immunization with either formulation induced
significant antibody production compared to control values (aP , 0.05). Immunization with LdcGCS-NIV induced significantly higher antibody levels
compared to LdcGCS alone on day 0 (bP , 0.04).
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carrier system altered the type of immune response generated.
Initial studies showed that immunization with 2 doses of 2 mg
LdcGCS did not protect against infection (mean liver parasite
burdens ± SE: control 276 ± 71, LdcGCS vaccinated 167 ± 41);
therefore, in subsequent studies, mice were immunized with 50 mg
recombinant protein. Immunization with this higher dose of
protein resulted in significant production of both IgG1- and
IgG2a-specific antibodies with the vesicular formulation inducing
significantly higher levels on the day of infection (day 0, P , 0.04;
Fig. 2). Specific stimulation of splenocytes from immunized mice
resulted in significant production of IFN-c (P, 0.05), but not IL-
10, IL-4, or nitrite, compared to corresponding unstimulated
controls with similar results for both vaccine formulations
(Fig. 3). In a second experiment, cells from immunized mice
produced significantly more IFN-c and IL-10 in response to
specific antigen stimulation compared with cells from non-
immunized mice (P , 0.05). IL-10 and IFN-c production by
cells from mice immunized with LdcGCS-NIV (mean IFN-c
production ng/ml ± SE; unstimulated cells 0.66 ± 0.66, antigen
stimulated cells 77.47 ± 18.25, mean IL-10 production ng/ml ±
SE; unstimulated cells 0.38 ± 0.17, antigen-stimulated cells 1.81 ±
0.51) were significantly higher than that of cells from mice
immunized with LdcGCS alone (mean IFN-c production ng/ml ±
SE; unstimulated cells 0 ± 0, antigen-stimulated cells 33.18 ±
4.55; mean IL-10 production ng/ml ± SE; unstimulated cells 0.21
± 0.14, antigen-stimulated cells 0.76 ± 0.09, P , 0.05). IL-4 and
nitrite production by cells from immunized mice were similar to
control values. Stimulation of cells from uninfected mice with
parasite antigen did not result in any increased production of
cytokines or nitrite over corresponding unstimulated control
(Fig. 3). ConA stimulation resulted in similar levels of IFN-c, IL-
4, IL-10, and nitrite production from immunized mice and
FIGURE 3. Mean IFN-c (A), IL-10 (B), IL-4 (C), and nitrite (D) production by splenocytes from mice taken on day 0 from mice immunized by
subcutaneous injection on days228 and214 with PBS (uninfected control), LdcGCS alone (50 mg protein), or LdcGCS-NIV (50 mg protein). Cells were
incubated with medium alone (control), LdcGCS protein (LdcGCS, 25 mg/ml), or Con A (5 mg/ml), and 72 hr later cell supernatants stored until nitrite or
cytokine levels could be determined by ELISA. aP , 0.05 compared to corresponding unstimulated control (unstim. control) value, bP, 0.05 compared
to stimulated cells from uninfected mice. Specific stimulation did not induce any significant increase in IL-4, IL-10, or nitrite compared to the relevant
unstimulated control for each group of mice. ConA stimulation induced similar cytokine and nitrite production by cells from each group of mice.
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uninfected control mice, a finding that was consistent in the
second experiment (Fig. 3).
Immunization with LdcGCS protected against infection with
L. donovani
An initial study was carried out to compare the effect of
vaccinating with LdcGCS and LPS to eliminate the possibility
that endotoxin present in LdcGCS preparations could be
responsible for any protection associated with vaccination.
Vaccination with LdcGCS gave protection in mice against
challenge infection, resulting in a significant reduction in liver
parasite burdens relative to control animals (P , 0.01), whereas
injection with LPS did not protect animals against L. donovani
infection (mean liver parasite burden ± SE, control 1,352 ± 151,
LdcGCS immunization 819 ± 62, LPS treatment 1,231 ± 150).
The effect of using a delivery system during immunization on
the outcome of infection was subsequently determined by
comparing the efficacy of immunization with LdcGCS protein
alone with that of LdcGCS incorporated in NIV. Both
formulations induced a similar significant reduction in liver
parasite burdens compared to control values (P , 0.01; Fig. 4),
indicating that using a carrier system did not enhance the ability
of the recombinant protein to protect against infection. Both
vaccines had no suppressive effect on splenic or bone marrow
parasite burdens because similar numbers were present in control
and vaccinated mice (Fig. 4).
Protection against infection was associated with a mixed
Th1:Th2 response post-infection
Specific IgG1 and IgG2a titers against the LdcGCS antigen
were similar in mice given either immunization type, but were
significantly higher than control values (P , 0.02; Fig. 5). In
contrast, IgG1 and IgG2a antibody titers against a parasite lysate
antigen (SAG) had a much lower titer and were similar for all 3
groups of mice.
Similar levels of IFN-c were induced by in vitro antigenic
stimulation of splenocytes derived from for all 3 groups of
infected mice. These levels were significantly greater than
produced by unstimulated splenocytes from the same sources (P
, 0.02) or from splenocytes derived from uninfected animals.
ConA stimulation resulted in the production of similar levels of
IFN-c by cells from uninfected and infected mice (Fig. 6A).
Infection with L. donovani was associated with IL-10 production
because significantly higher levels were produced by splenocytes
derived from all 3 groups of infected mice compared with
uninfected controls (P , 0.05; Fig. 6B). Immunization was not
associated with an increase in IL-10 production as splenocytes
FIGURE 4. The effect of vaccination with LdcGCS formulations on the
L. donovani spleen, liver, and bone marrow burdens of control and
immunized mice. Mice were immunized by subcutaneous injection with
PBS (uninfected control) or 50 mg LdcGCS alone (LdcGCS) or 50 mg
LdcGCS-NIV (LdcGCS-NIV) on days228 and214. On day 0, mice were
infected with L. donovani, and parasite burdens in the spleen, liver, and
bone marrow determined on day 33 PI. aP , 0.01 compared to
control values.
FIGURE 5. The effect of vaccination with LdcGCS on IgG1 (A) and IgG2a (B) specific antibody responses of mice from Fig. 4 to 2 different L.
donovani antigens (LdcGCS and SAG). aP , 0.02 compared to infected control value.
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from infected, non-immunized animals stimulated with the
recombinant antigen produced as much cytokine as immunized
mice. Stimulation with ConA did not induce a significant increase
in IL-10 production compared with unstimulated levels for all 3
groups of infected mice, whereas splenocytes from uninfected
mice produced significantly higher levels compared to their
unstimulated controls (P , 0.05, Fig. 6B). IL-4 production by
cells from infected mice in all 3 groups was similarly low, even
after ConA stimulation (,0.04 ng/ml for all treatment groups).
Only cells from uninfected, non-immunized animals stimulated
with ConA produced enhanced levels of IL-4 compared with
unstimulated controls values (mean IL-4 production, ng/ml ± SE:
unstimulated control 0.031± 0.031, ConA stimulated 0.125 ±
0.04). Cells from all 4 groups of mice incubated with medium,
antigen, or ConA had similar levels of IL-5 present in their
supernatants (Fig. 6C). Unstimulated cells from all 3 groups of L.
donovani infected mice had high levels of nitrite in their
supernatants, and stimulation with antigen or Con A did not
modify their nitrite production. In contrast, cells from uninfected
mice produced very little nitrite, and ConA stimulation did not
induce the levels present in unstimulated controls from infected
mice (Fig. 6D).
DISCUSSION
The results of this study demonstrate that vaccination with the
recombinant fusion protein LdcGCS protected against L.
donovani infection. The level of protection obtained after
immunization with 2 doses of 50-mg LdcGCS protein/dose, based
on reduction in liver parasite burdens, was not appreciably
different from that achieved in previous studies using an LdcGCS
DNA-based vaccine (Carter et al., 2007). This perhaps is not
surprising since studies have shown that DNA vaccines are more
effective than their respective recombinant protein vaccine
(Dumonteil, 2007). It may be possible to increase the efficacy of
vaccination by increasing the amount of LdcGCS protein used to
FIGURE 6. Mean IFN-c (A), IL-10 (B), IL-5 (C), and nitrite (D) production by splenocytes of mice from Fig. 4. aP , 0.02 for stimulated cells
compared to corresponding unstimulated control cells; bP , 0.02 compared to infected group.
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immunize mice, or by using a ‘prime-boost’ approach in which
mice are primed with the LdcGCS DNA vaccine and boosted
with recombinant LdcGCS protein, or by using another
Leishmania sp. antigen in the vaccine formulation, or by including
other agents, such as cytokines, in the vaccine formulation to
boost the immune response. Immunizing with multiple antigens is
now regarded by many researchers as being inevitable, and DNA
constructs that contain the gene sequence for multiple Leishmania
sp. proteins are being developed as potential vaccines, e.g., Leish-
111f encodes for 3 leishmanial proteins (Ghalib and Modabber,
2007).
Incorporating LdcGCS into a NIV formulation was more
effective than immunization with LdcGCS alone based on its
ability to induce specific antibody pre- and post-infection.
However, the vesicular formulation gave a similar level of
protection as immunization with LdcGCS alone. In previous
studies, we have shown that immunization with modified
gonadotrophin hormone-NIV formulation to induce castration
of male rats (4 doses, 10 mg/dose) induced a predominant Th2
response (Ferro et al., 2004), whereas in the present study
immunization with LdcGCS induced a mixed Th1/Th2 response.
The difference in results could be due to the different species,
antigen used, or dosing regimen. Using vesicular systems to
deliver antigen can increase the efficacy of a protein vaccine in a
number of ways, e.g., by improving uptake by antigen presenting
cells or providing an antigen depot (Perrie et al., 2008). Protection
against L. donovani infection is ultimately dependent on the
ability to stimulate macrophage killing of the intracellular
parasite, and many studies have shown that susceptibility to L.
donovani is associated with a reduced ability to produce IFN-c
and an increased ability to produce IL-10 (Nyle´n and Sacks, 2007;
Ganguly et al., 2008). Therefore the ability of vaccination with
LdcGCS alone or LdcGCS-NIV to protect against infection and
enhance IFN-c production by splenocytes from immunized mice
pre-infection is not surprising. The present study and a previous
one using the DNA vaccine (Carter et al., 2007) have indicated
that vaccine formulations can be screened on the basis of their
ability to induce specific IgG1 and IgG2a antibodies and their
ability to prime IFN-c production by splenocytes. The inability of
either formulation to modify immune responses after infection
despite causing a reduction in parasite burdens may be a feature
of the experimental model used in the present study, i.e., the
parasite strain used or that mice were infected with a large
number of amastigote parasites. In previous studies, an alteration
in immune responses of mice cured of their L. donovani infection
by drug treatment did not occur until after day 31 post-treatment
(Banduwardene et al., 1997). Thus, cured mice had a positive
DTH response instead of a negative DTH response to promas-
tigote parasites injected into the footpad by day 31 post-treatment
and increased IFN-c production by ex vivo antigen-stimulated
splenocytes compared to infected controls by splenocytes was not
obtained until day 42 post-treatment. These results perhaps
indicate that changes in immune responses require removal of
dead parasites or antigens before protective T cell responses
associated with protection in L. donovani can be expressed. Here,
there was only partial parasite clearance, and it is not surprising
that the immune responses induced by infection predominate.
Expression of LdcGCS resulted in production of full-length
and truncated forms of the protein. Inclusion of protein inhibitors
during production did not increase the recovery of full-length
protein in the soluble fraction, suggesting that truncated versions
were made after induction. The his-tag has been cloned into the
‘N-terminus’ of the protein so that when the protein was purified
the truncated versions were also selected. Protein refolding
occurred when the protein was dialyzed because it showed
activity in assays carried out to determine the enzymatic activity
of LdcGCS (data not shown). Similar problems with protein
expression are common (Qoronfleh et al., 2007). Endotoxin
contamination is inevitable as the protein is expressed in bacteria,
but it can be removed using a variety of methods whose success is
dependent on the characteristics of the protein (Magalha˜es et al.,
2007). The maximum level of endotoxin contamination for
parenteral products is 5 EU/kg/hr in most countries (Magalha˜es
et al., 2007), which was easily avoided here where mice were
immunized with ,0.5 EU each.
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